An in vitro model for the Allergen-IgE-FcεRI interaction

Sylvia Laffer, Erik Hogbom, Jonas Adrianson, Hans Grönlund, Christian Sillaber, Peter Valent, Luca Vangelista, Franz Kricek, Dietrich Kraft, Rudolf Valenta

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The interaction of immune complexes consisting of allergens and allergen-specific IgE with the high-affinity Fcε receptor represents the key event in the induction of symptoms in type I allergic individuals. Immediate-type symptoms result from the release of biological mediators due to allergen-induced cross-linking of FcεRI receptors on mast cells and basophils, whereas FcεRI-mediated presentation of allergen-IgE complexes may contribute to late-phase symptoms through enhanced T cell activation. The interaction of allergens/allergen-specific IgE/FcεRI represents, therefore, an important target for therapeutic intervention strategies in type I allergy. Methods and Results: A molecular model of the allergen-IgE-FcεRI interaction was established. It consists of recombinant purified Bet v 1, the major birch pollen allergen, a chimeric Bet v 1 specific monoclonal IgE antibody, and the baculovirus-expressed purified human alpha chain of FcεRI. The chimeric Bet v 1-specific IgE antibody consists of the light chain and the heavy chain variable region of a mouse monoclonal Bet v 1 specific antibody, Bip 1, and the constant region of human IgE. The interaction of rBet v 1, chimeric Bip 1, and human alpha chain was investigated by overlay experiments. Nitrocellulose-immobi lized recombinant alpha chains was incubated with chimeric Bip 1 and, for control purposes, with mouse-derived Bip 1. Bound chimeric Bip 1 was detected with 125]-labeled rBet v 1. The specific interaction of rBetv 1, chimeric Bip 1, and recombinant human alpha chain is demonstrated. We thus establish a molecular model of the allergen/IgE/alpha chain interaction. The usefulness of the described in vitro system is exemplified by the identification of a mouse monoclonal antihuman IgE antibody which blocked the IgE-alpha chain interaction. Conclusions: The module system consisting of rBet v 1, chimeric Bip 1, and recombinant alpha chain may be used for the identification of competitors of the allergic effector reaction by means of high throughput screening of compounds or by combinatorial chemistry.

Original languageEnglish
Pages (from-to)116-118
Number of pages3
JournalInternational Archives of Allergy and Immunology
Volume118
Issue number2-4
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Allergens
Immunoglobulin E
Molecular Models
Antibodies
Hypersensitivity
In Vitro Techniques
Betula
Collodion
Basophils
Fc Receptors
Baculoviridae
Pollen
Antigen-Antibody Complex
Mast Cells
Monoclonal Antibodies
T-Lymphocytes
Light

Keywords

  • rBet v 1
  • rBet v 1 specific chimeric IgE
  • Recombinant allergen
  • Recombinant Fcε receptor alpha chain
  • Type 1 allergy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Laffer, S., Hogbom, E., Adrianson, J., Grönlund, H., Sillaber, C., Valent, P., ... Valenta, R. (1999). An in vitro model for the Allergen-IgE-FcεRI interaction. International Archives of Allergy and Immunology, 118(2-4), 116-118.

An in vitro model for the Allergen-IgE-FcεRI interaction. / Laffer, Sylvia; Hogbom, Erik; Adrianson, Jonas; Grönlund, Hans; Sillaber, Christian; Valent, Peter; Vangelista, Luca; Kricek, Franz; Kraft, Dietrich; Valenta, Rudolf.

In: International Archives of Allergy and Immunology, Vol. 118, No. 2-4, 1999, p. 116-118.

Research output: Contribution to journalArticle

Laffer, S, Hogbom, E, Adrianson, J, Grönlund, H, Sillaber, C, Valent, P, Vangelista, L, Kricek, F, Kraft, D & Valenta, R 1999, 'An in vitro model for the Allergen-IgE-FcεRI interaction', International Archives of Allergy and Immunology, vol. 118, no. 2-4, pp. 116-118.
Laffer S, Hogbom E, Adrianson J, Grönlund H, Sillaber C, Valent P et al. An in vitro model for the Allergen-IgE-FcεRI interaction. International Archives of Allergy and Immunology. 1999;118(2-4):116-118.
Laffer, Sylvia ; Hogbom, Erik ; Adrianson, Jonas ; Grönlund, Hans ; Sillaber, Christian ; Valent, Peter ; Vangelista, Luca ; Kricek, Franz ; Kraft, Dietrich ; Valenta, Rudolf. / An in vitro model for the Allergen-IgE-FcεRI interaction. In: International Archives of Allergy and Immunology. 1999 ; Vol. 118, No. 2-4. pp. 116-118.
@article{935052f2626b4007b0567d150abe960d,
title = "An in vitro model for the Allergen-IgE-FcεRI interaction",
abstract = "Background: The interaction of immune complexes consisting of allergens and allergen-specific IgE with the high-affinity Fcε receptor represents the key event in the induction of symptoms in type I allergic individuals. Immediate-type symptoms result from the release of biological mediators due to allergen-induced cross-linking of FcεRI receptors on mast cells and basophils, whereas FcεRI-mediated presentation of allergen-IgE complexes may contribute to late-phase symptoms through enhanced T cell activation. The interaction of allergens/allergen-specific IgE/FcεRI represents, therefore, an important target for therapeutic intervention strategies in type I allergy. Methods and Results: A molecular model of the allergen-IgE-FcεRI interaction was established. It consists of recombinant purified Bet v 1, the major birch pollen allergen, a chimeric Bet v 1 specific monoclonal IgE antibody, and the baculovirus-expressed purified human alpha chain of FcεRI. The chimeric Bet v 1-specific IgE antibody consists of the light chain and the heavy chain variable region of a mouse monoclonal Bet v 1 specific antibody, Bip 1, and the constant region of human IgE. The interaction of rBet v 1, chimeric Bip 1, and human alpha chain was investigated by overlay experiments. Nitrocellulose-immobi lized recombinant alpha chains was incubated with chimeric Bip 1 and, for control purposes, with mouse-derived Bip 1. Bound chimeric Bip 1 was detected with 125]-labeled rBet v 1. The specific interaction of rBetv 1, chimeric Bip 1, and recombinant human alpha chain is demonstrated. We thus establish a molecular model of the allergen/IgE/alpha chain interaction. The usefulness of the described in vitro system is exemplified by the identification of a mouse monoclonal antihuman IgE antibody which blocked the IgE-alpha chain interaction. Conclusions: The module system consisting of rBet v 1, chimeric Bip 1, and recombinant alpha chain may be used for the identification of competitors of the allergic effector reaction by means of high throughput screening of compounds or by combinatorial chemistry.",
keywords = "rBet v 1, rBet v 1 specific chimeric IgE, Recombinant allergen, Recombinant Fcε receptor alpha chain, Type 1 allergy",
author = "Sylvia Laffer and Erik Hogbom and Jonas Adrianson and Hans Gr{\"o}nlund and Christian Sillaber and Peter Valent and Luca Vangelista and Franz Kricek and Dietrich Kraft and Rudolf Valenta",
year = "1999",
language = "English",
volume = "118",
pages = "116--118",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "2-4",

}

TY - JOUR

T1 - An in vitro model for the Allergen-IgE-FcεRI interaction

AU - Laffer, Sylvia

AU - Hogbom, Erik

AU - Adrianson, Jonas

AU - Grönlund, Hans

AU - Sillaber, Christian

AU - Valent, Peter

AU - Vangelista, Luca

AU - Kricek, Franz

AU - Kraft, Dietrich

AU - Valenta, Rudolf

PY - 1999

Y1 - 1999

N2 - Background: The interaction of immune complexes consisting of allergens and allergen-specific IgE with the high-affinity Fcε receptor represents the key event in the induction of symptoms in type I allergic individuals. Immediate-type symptoms result from the release of biological mediators due to allergen-induced cross-linking of FcεRI receptors on mast cells and basophils, whereas FcεRI-mediated presentation of allergen-IgE complexes may contribute to late-phase symptoms through enhanced T cell activation. The interaction of allergens/allergen-specific IgE/FcεRI represents, therefore, an important target for therapeutic intervention strategies in type I allergy. Methods and Results: A molecular model of the allergen-IgE-FcεRI interaction was established. It consists of recombinant purified Bet v 1, the major birch pollen allergen, a chimeric Bet v 1 specific monoclonal IgE antibody, and the baculovirus-expressed purified human alpha chain of FcεRI. The chimeric Bet v 1-specific IgE antibody consists of the light chain and the heavy chain variable region of a mouse monoclonal Bet v 1 specific antibody, Bip 1, and the constant region of human IgE. The interaction of rBet v 1, chimeric Bip 1, and human alpha chain was investigated by overlay experiments. Nitrocellulose-immobi lized recombinant alpha chains was incubated with chimeric Bip 1 and, for control purposes, with mouse-derived Bip 1. Bound chimeric Bip 1 was detected with 125]-labeled rBet v 1. The specific interaction of rBetv 1, chimeric Bip 1, and recombinant human alpha chain is demonstrated. We thus establish a molecular model of the allergen/IgE/alpha chain interaction. The usefulness of the described in vitro system is exemplified by the identification of a mouse monoclonal antihuman IgE antibody which blocked the IgE-alpha chain interaction. Conclusions: The module system consisting of rBet v 1, chimeric Bip 1, and recombinant alpha chain may be used for the identification of competitors of the allergic effector reaction by means of high throughput screening of compounds or by combinatorial chemistry.

AB - Background: The interaction of immune complexes consisting of allergens and allergen-specific IgE with the high-affinity Fcε receptor represents the key event in the induction of symptoms in type I allergic individuals. Immediate-type symptoms result from the release of biological mediators due to allergen-induced cross-linking of FcεRI receptors on mast cells and basophils, whereas FcεRI-mediated presentation of allergen-IgE complexes may contribute to late-phase symptoms through enhanced T cell activation. The interaction of allergens/allergen-specific IgE/FcεRI represents, therefore, an important target for therapeutic intervention strategies in type I allergy. Methods and Results: A molecular model of the allergen-IgE-FcεRI interaction was established. It consists of recombinant purified Bet v 1, the major birch pollen allergen, a chimeric Bet v 1 specific monoclonal IgE antibody, and the baculovirus-expressed purified human alpha chain of FcεRI. The chimeric Bet v 1-specific IgE antibody consists of the light chain and the heavy chain variable region of a mouse monoclonal Bet v 1 specific antibody, Bip 1, and the constant region of human IgE. The interaction of rBet v 1, chimeric Bip 1, and human alpha chain was investigated by overlay experiments. Nitrocellulose-immobi lized recombinant alpha chains was incubated with chimeric Bip 1 and, for control purposes, with mouse-derived Bip 1. Bound chimeric Bip 1 was detected with 125]-labeled rBet v 1. The specific interaction of rBetv 1, chimeric Bip 1, and recombinant human alpha chain is demonstrated. We thus establish a molecular model of the allergen/IgE/alpha chain interaction. The usefulness of the described in vitro system is exemplified by the identification of a mouse monoclonal antihuman IgE antibody which blocked the IgE-alpha chain interaction. Conclusions: The module system consisting of rBet v 1, chimeric Bip 1, and recombinant alpha chain may be used for the identification of competitors of the allergic effector reaction by means of high throughput screening of compounds or by combinatorial chemistry.

KW - rBet v 1

KW - rBet v 1 specific chimeric IgE

KW - Recombinant allergen

KW - Recombinant Fcε receptor alpha chain

KW - Type 1 allergy

UR - http://www.scopus.com/inward/record.url?scp=0032915219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032915219&partnerID=8YFLogxK

M3 - Article

VL - 118

SP - 116

EP - 118

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 2-4

ER -